Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 10/20 | 0.49 |
| ▸ | TCF4 | P15884 | 7/20 | 0.49 |
| ▸ | CDH1 | P12830 | 2/20 | 0.44 |
| ▸ | APC | P25054 | 2/20 | 0.44 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BCL9 | O00512 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498425 | 0.74 | CTNNB1 (0.37) | CTNNB1TCF4MAPTSMN1; SMN2KMT2A | |
| SCHEMBL13121634 | 0.74 | CTNNB1 (0.49) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL31643973 | 0.74 | CYP3A4 (0.37) | CTNNB1TCF4MAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL31134383 | 0.72 | CTNNB1 (0.64) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL3673245 | 0.69 | MGAM (0.40) | CTNNB1TCF4CYP3A4 | |
| SCHEMBL29711243 | 0.69 | CTNNB1 (0.81) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL29711326 | 0.69 | CTNNB1 (0.78) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL29711331 | 0.67 | CTNNB1 (0.76) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL29711267 | 0.66 | CTNNB1 (0.68) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL29929662 | 0.66 | CTNNB1 (0.68) | CTNNB1TCF4CDH1APCTCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399188-B1 | PERYLENEQUINONES FOR USE AS SONOSENSITIZERS | UNIV ALBERTA (CA) | 2008-01-16 | — | — | EP | claimed |
| EP-1357944-B1 | PERYLENEQUINONES FOR USE WITH IMMUNOTHERAPY AGENTS | ALTACHEM PHARMA LTD (CA) | 2007-06-13 | — | — | EP | claimed |
| US-20040110846-A1 | derivatives of perylenequinone pigments (PQPs) having both photosensitizing properties and sonosensitizing properties are used to treat diseases and other conditions by modulating the body's existing immune system, and/or any immunotherapies | QUEST PHARMATECH INC. (CA) | 2004-06-10 | — | — | US | claimed |
| US-20020143066-A1 | Perylenequinones for use as photosensitizers and sonosensitizers | ALTACHEM PHARMA, LTD. (CA) | 2002-10-03 | — | — | US | claimed |
| US-20080255498-A1 | Sensitizer Solutions, Systems, and Methods of Use | OROSCIENCE, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1933941-A2 | TREATMENT SYSTEMS FOR DELIVERY OF SENSITIZER SOLUTIONS | Houle, Philip R. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007025244-A2 | TREATMENT SYSTEMS FOR DELIVERY OF SENSITIZER SOLUTIONS | HOULE PHILIP R (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1015033-A2 | SUBSTITUTED PERYLENEQUINONES FOR USE IN PHOTODYNAMIC THERAPY | AltaRex, Corp. (CA) | 2000-07-05 | — | — | EP | disclosed |
| EP-1015033-A4 | SUBSTITUTED PERYLENEQUINONES FOR USE IN PHOTODYNAMIC THERAPY | ALTAREX INC (CA) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998033470-A2 | SUBSTITUTED PERYLENEQUINONES FOR USE IN PHOTODYNAMIC THERAPY | ALTAREX CORP. (CA) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110846-A1 | derivatives of perylenequinone pigments (PQPs) having both photosensitizing properties and sonosensitizing properties are used to treat diseases and other conditions by modulating the body's existing immune system, and/or any immunotherapies | IL2, IFNG, LY96 | CTNNB1 2720/4885TCF4 2115/4885CDH1 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.